Eliane Sardh Selected Research

Acute Intermittent Porphyria (Porphyria, Acute)

1/2022	RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
11/2021	A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
9/2021	Treatment with assisted reproduction technologies in women with acute hepatic porphyria.
12/2020	Challenges in the management of acute intermittent porphyria with recurrent attacks during pregnancy: A case report.
11/2020	Givosiran for Acute Intermittent Porphyria. Reply.
11/2020	Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
1/2019	Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
9/2015	Vitamin D-binding protein as a biomarker of active disease in acute intermittent porphyria.
1/2012	Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.
6/2010	Combined liver and kidney transplantation in acute intermittent porphyria.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eliane Sardh Research Topics

Disease

13	Acute Intermittent Porphyria (Porphyria, Acute) 01/2022 - 04/2006
6	Porphyrias (Porphyria) 01/2022 - 06/2010
2	Liver Neoplasms (Liver Cancer) 01/2022 - 11/2013
2	Pain (Aches) 01/2022 - 11/2020
2	Body Weight (Weight, Body) 11/2020 - 01/2019
1	Rare Diseases (Rare Disease) 01/2021
1	Injection Site Reaction 11/2020
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2020
1	Renal Insufficiency (Renal Failure) 01/2012
1	Chronic Renal Insufficiency 01/2012
1	Metabolic Diseases (Metabolic Disease) 03/2009

Drug/Important Bio-Agent (IBA)

8	Heme (Haem)IBA 01/2022 - 04/2006
6	Acute Hepatic PorphyriaIBA 01/2022 - 11/2013
6	givosiranIBA 01/2022 - 01/2019
6	PorphobilinogenIBA 01/2022 - 04/2006
3	Hemin (Panhematin)FDA Link 01/2022 - 11/2020
3	Hydroxymethylbilane Synthase (Porphobilinogen Deaminase)IBA 09/2015 - 01/2007
3	PorphyrinsIBA 01/2012 - 04/2006
2	Aminolevulinic Acid (Levulan)FDA Link 01/2022 - 01/2019
2	EnzymesIBA 11/2021 - 01/2007
2	Biomarkers (Surrogate Marker)IBA 09/2015 - 03/2009
2	AcidsIBA 01/2012 - 04/2006
1	Cytochrome P-450 CYP2C19IBA 11/2021
1	Caffeine (No Doz)FDA LinkGeneric 11/2021
1	Dextromethorphan (Racemethorphan)FDA LinkGeneric 11/2021
1	Midazolam (Versed)FDA LinkGeneric 11/2021
1	Omeprazole (Prilosec)FDA LinkGeneric 11/2021
1	Cytochrome P-450 CYP1A2 (CYP1A2)IBA 11/2021
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 11/2021
1	Losartan (Cozaar)FDA LinkGeneric 11/2021
1	Cytochrome P-450 CYP3AIBA 11/2021
1	Cytochrome P-450 CYP2C9IBA 11/2021
1	heme arginateIBA 12/2020
1	CreatinineIBA 11/2020
1	Transaminases (Aminotransferases)IBA 11/2020
1	Messenger RNA (mRNA)IBA 01/2019
1	Vitamin D-Binding ProteinIBA 09/2015
1	Phenobarbital (Luminal)FDA Link 01/2007

Therapy/Procedure

2	RNAi Therapeutics 01/2022 - 11/2020
2	Intravenous Administration 01/2022 - 11/2020
1	Genomic Medicine 01/2021
1	Injections 01/2019
1	Therapeutics 01/2019
1	Subcutaneous Injections 01/2019
1	Liver Transplantation 09/2015
1	Nephrectomy 01/2012
1	Kidney Transplantation 06/2010
1	Transplantation 06/2010
1	Enzyme Replacement Therapy 01/2007